Palatin Technologies Inc
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is… Read more
Palatin Technologies Inc (PTN) - Net Assets
Latest net assets as of March 2025: $-6.39 Million USD
Based on the latest financial reports, Palatin Technologies Inc (PTN) has net assets worth $-6.39 Million USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.73 Million) and total liabilities ($10.12 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-6.39 Million |
| % of Total Assets | -171.31% |
| Annual Growth Rate | N/A |
| 5-Year Change | -100.14% |
| 10-Year Change | -100.91% |
| Growth Volatility | 484.65 |
Palatin Technologies Inc - Net Assets Trend (1996–2024)
This chart illustrates how Palatin Technologies Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Palatin Technologies Inc (1996–2024)
The table below shows the annual net assets of Palatin Technologies Inc from 1996 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-06-30 | $-111.50K | -183.16% |
| 2023-06-30 | $134.07K | -99.18% |
| 2022-06-30 | $16.27 Million | -67.24% |
| 2021-06-30 | $49.65 Million | -38.07% |
| 2020-06-30 | $80.17 Million | -20.27% |
| 2019-06-30 | $100.55 Million | +272.89% |
| 2018-06-30 | $26.96 Million | +622.11% |
| 2017-06-30 | $-5.16 Million | +70.63% |
| 2016-06-30 | $-17.59 Million | -244.09% |
| 2015-06-30 | $12.20 Million | +24.68% |
| 2014-06-30 | $9.79 Million | -57.40% |
| 2013-06-30 | $22.98 Million | +1155.03% |
| 2012-06-30 | $1.83 Million | -89.94% |
| 2011-06-30 | $18.19 Million | +95.23% |
| 2010-06-30 | $9.32 Million | +181.22% |
| 2009-06-30 | $3.31 Million | -49.43% |
| 2008-06-30 | $6.55 Million | -64.64% |
| 2007-06-30 | $18.53 Million | +1.27% |
| 2006-06-30 | $18.30 Million | +98.37% |
| 2005-06-30 | $9.23 Million | -52.41% |
| 2004-06-30 | $19.39 Million | +3.91% |
| 2003-06-30 | $18.66 Million | +114.77% |
| 2002-06-30 | $8.69 Million | -27.10% |
| 2001-06-30 | $11.92 Million | +72.56% |
| 2000-06-30 | $6.91 Million | +2201.72% |
| 1999-06-30 | $300.00K | -91.18% |
| 1998-06-30 | $3.40 Million | -65.31% |
| 1997-06-30 | $9.80 Million | +245.29% |
| 1996-06-30 | $2.84 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Palatin Technologies Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 43363361200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $179.27K | % |
| Other Comprehensive Income | $-179.31K | % |
| Other Components | $441.66 Million | % |
| Total Equity | $-111.50K | 100.00% |
Palatin Technologies Inc Competitors by Market Cap
The table below lists competitors of Palatin Technologies Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
RENAISSANCERE HLDG
BE:RRJ
|
$2.45 Million |
|
UCB - Dusseldorf Stock Exchang
DU:UNC
|
$2.45 Million |
|
Inix Technologies Holdings Bhd
KLSE:0094
|
$2.45 Million |
|
SYNEX RENE. ENERGY CORP.
F:V5X
|
$2.45 Million |
|
CREDICORP
BE:D8V
|
$2.45 Million |
|
Par Drugs And Chemicals Limited
NSE:PAR
|
$2.45 Million |
|
Saigon General Service Corp
VN:SVC
|
$2.44 Million |
|
JATCORP LTD.
F:3J2
|
$2.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Palatin Technologies Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 134,073 to -111,497, a change of -245,570 (-183.2%).
- Net loss of 29,736,113 reduced equity.
- Share repurchases of 56,401 reduced equity.
- New share issuances of 14,666,042 increased equity.
- Other comprehensive income decreased equity by 62,739.
- Other factors increased equity by 14,943,641.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-29.74 Million | -26669.88% |
| Share Repurchases | $56.40K | -50.59% |
| Share Issuances | $14.67 Million | +13153.75% |
| Other Comprehensive Income | $-62.74K | -56.27% |
| Other Changes | $14.94 Million | +13402.73% |
| Total Change | $- | -183.16% |
Book Value vs Market Value Analysis
This analysis compares Palatin Technologies Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-06-30 | $1182.59 | $23.00 | x |
| 1997-06-30 | $837.89 | $23.00 | x |
| 1998-06-30 | $264.76 | $23.00 | x |
| 1999-06-30 | $12.63 | $23.00 | x |
| 2000-06-30 | $232.00 | $23.00 | x |
| 2001-06-30 | $294.04 | $23.00 | x |
| 2002-06-30 | $152.99 | $23.00 | x |
| 2003-06-30 | $164.45 | $23.00 | x |
| 2004-06-30 | $101.63 | $23.00 | x |
| 2005-06-30 | $42.82 | $23.00 | x |
| 2006-06-30 | $75.80 | $23.00 | x |
| 2007-06-30 | $60.80 | $23.00 | x |
| 2008-06-30 | $19.22 | $23.00 | x |
| 2009-06-30 | $9.59 | $23.00 | x |
| 2010-06-30 | $23.62 | $23.00 | x |
| 2011-06-30 | $22.64 | $23.00 | x |
| 2012-06-30 | $1.31 | $23.00 | x |
| 2013-06-30 | $5.88 | $23.00 | x |
| 2014-06-30 | $2.29 | $23.00 | x |
| 2015-06-30 | $2.52 | $23.00 | x |
| 2016-06-30 | $-2.81 | $23.00 | x |
| 2017-06-30 | $-0.70 | $23.00 | x |
| 2018-06-30 | $3.26 | $23.00 | x |
| 2019-06-30 | $11.58 | $23.00 | x |
| 2020-06-30 | $8.54 | $23.00 | x |
| 2021-06-30 | $5.25 | $23.00 | x |
| 2022-06-30 | $1.70 | $23.00 | x |
| 2023-06-30 | $0.01 | $23.00 | x |
| 2024-06-30 | $-0.01 | $23.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Palatin Technologies Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -662.26%
- • Asset Turnover: 0.42x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-968.09%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | -121.20% | -17200.00% | 0.00x | 2.48x | $-3.72 Million |
| 1997 | -54.08% | -757.14% | 0.05x | 1.44x | $-6.28 Million |
| 1998 | -291.18% | -9900.00% | 0.02x | 1.91x | $-10.24 Million |
| 1999 | -4000.00% | -2000.00% | 0.13x | 15.67x | $-12.03 Million |
| 2000 | -118.51% | -159.92% | 0.58x | 1.29x | $-8.87 Million |
| 2001 | -88.95% | -592.77% | 0.13x | 1.20x | $-11.79 Million |
| 2002 | -185.78% | -5736.02% | 0.02x | 1.42x | $-17.01 Million |
| 2003 | -110.23% | -1619.29% | 0.06x | 1.22x | $-22.43 Million |
| 2004 | -135.75% | -1136.76% | 0.09x | 1.26x | $-28.26 Million |
| 2005 | -155.64% | -79.96% | 0.51x | 3.81x | $-15.28 Million |
| 2006 | -158.25% | -146.64% | 0.49x | 2.19x | $-30.79 Million |
| 2007 | -149.75% | -192.64% | 0.34x | 2.31x | $-29.60 Million |
| 2008 | -219.54% | -125.26% | 0.60x | 2.92x | $-15.04 Million |
| 2009 | -144.93% | -42.30% | 0.86x | 3.98x | $-5.13 Million |
| 2010 | -19.24% | -12.64% | 1.14x | 1.33x | $-2.72 Million |
| 2011 | -70.45% | -868.61% | 0.07x | 1.16x | $-14.64 Million |
| 2012 | -942.33% | -23398.58% | 0.01x | 2.94x | $-17.44 Million |
| 2013 | -90.79% | -201352.90% | 0.00x | 1.09x | $-23.16 Million |
| 2014 | -142.29% | 0.00% | 0.00x | 1.28x | $-14.91 Million |
| 2015 | -144.75% | -136.40% | 0.44x | 2.42x | $-18.89 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-49.95 Million |
| 2017 | 0.00% | -29.81% | 0.79x | 0.00x | $-12.82 Million |
| 2018 | 91.61% | 36.80% | 1.72x | 1.45x | $22.01 Million |
| 2019 | 35.58% | 59.32% | 0.58x | 1.04x | $25.72 Million |
| 2020 | -27.92% | -18969.53% | 0.00x | 1.06x | $-30.40 Million |
| 2021 | -67.61% | 0.00% | 0.00x | 1.36x | $-38.53 Million |
| 2022 | -220.12% | -2438.49% | 0.04x | 2.22x | $-37.43 Million |
| 2023 | -20542.46% | -567.44% | 0.27x | 133.80x | $-27.56 Million |
| 2024 | 0.00% | -662.26% | 0.42x | 0.00x | $-29.72 Million |
Industry Comparison
This section compares Palatin Technologies Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Palatin Technologies Inc (PTN) | $-6.39 Million | -121.20% | N/A | $2.45 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |